'Small' randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good?

被引：4

作者：

Bonnefoi, H

机构：

[1] Univ Hosp Geneva, Dept Gynecol, Breast & Gynaecol Oncol Med Unit, CH-1211 Geneva, Switzerland

[2] Univ Hosp Geneva, Dept Med, Breast & Gynaecol Oncol Med Unit, CH-1211 Geneva, Switzerland

来源：

ANNALS OF ONCOLOGY | 2005年 / 16卷 / 09期

关键词：

D O I：

10.1093/annonc/mdi288

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1407 / 1410

页数：4

共 22 条

[21] Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer:: The GEPARDUO Study of the German Breast Group [J].

von Minckwitz, G ;

Raab, G ;

Caputo, A ;

Schütte, M ;

Hilfrich, F ;

Blohmer, JU ;

Gerber, B ;

Costa, SD ;

Merkle, E ;

Eidtmann, H ;

Lampe, D ;

Jackisch, C ;

du Bois, A ;

Kaufmann, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2676-2685

[22] Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study [J].

von Minckwitz, G ;

Costa, SD ;

Raab, G ;

Blohmer, JU ;

Eidtmann, H ;

Hilfrich, J ;

Merkle, E ;

Jackisch, C ;

Gademann, G ;

Tulusan, AH ;

Eiermann, W ;

Graf, E ;

Kaufmann, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) :3506-3515

← 1 2 3 →